Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary efficacy evaluation will be based on three primary efficacy variables: • Assessability • Sensitivity • Specificity which will be calculated for both gadobutrol-enhanced MRA and non-contrast ToF MRA. These will be used to evaluate five co-primary endpoints: - Proportion of assessable vascular segments - Sensitivity for detection of clinically significant disease [70 to 99% stenosis] on a segmental basis - Specificity for exclusion of clinically significant disease [70 to 99% stenosis] on a segmental basis - The two minimum gadobutrol performance criteria: Sensitivity > 50% Specificity > 50%
Critère d'inclusion
- Subjects with known or suspected vascular disease of the supra-aortic vessels